These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 21352504)
1. Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers. Jones LH; Allan G; Corbau R; Middleton DS; Mowbray CE; Newman SD; Phillips C; Webster R; Westby M Chem Biol Drug Des; 2011 May; 77(5):393-7. PubMed ID: 21352504 [TBL] [Abstract][Full Text] [Related]
2. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Mowbray CE; Burt C; Corbau R; Gayton S; Hawes M; Perros M; Tran I; Price DA; Quinton FJ; Selby MD; Stupple PA; Webster R; Wood A Bioorg Med Chem Lett; 2009 Oct; 19(20):5857-60. PubMed ID: 19748778 [TBL] [Abstract][Full Text] [Related]
3. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. Li D; Zhan P; De Clercq E; Liu X J Med Chem; 2012 Apr; 55(8):3595-613. PubMed ID: 22268494 [No Abstract] [Full Text] [Related]
4. Pyrazole NNRTIs 1: design and initial optimisation of a novel template. Mowbray CE; Burt C; Corbau R; Perros M; Tran I; Stupple PA; Webster R; Wood A Bioorg Med Chem Lett; 2009 Oct; 19(19):5599-602. PubMed ID: 19709880 [TBL] [Abstract][Full Text] [Related]
5. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. Fätkenheuer G; Staszewski S; Plettenburg A; Hackman F; Layton G; McFadyen L; Davis J; Jenkins TM AIDS; 2009 Oct; 23(16):2115-22. PubMed ID: 19779321 [TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. Gomez R; Jolly SJ; Williams T; Vacca JP; Torrent M; McGaughey G; Lai MT; Felock P; Munshi V; Distefano D; Flynn J; Miller M; Yan Y; Reid J; Sanchez R; Liang Y; Paton B; Wan BL; Anthony N J Med Chem; 2011 Nov; 54(22):7920-33. PubMed ID: 21985673 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204 [TBL] [Abstract][Full Text] [Related]
8. Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif. Su DS; Lim JJ; Tinney E; Tucker TJ; Saggar S; Sisko JT; Wan BL; Young MB; Anderson KD; Rudd D; Munshi V; Bahnck C; Felock PJ; Lu M; Lai MT; Touch S; Moyer G; Distefano DJ; Flynn JA; Liang Y; Sanchez R; Perlow-Poehnelt R; Miller M; Vacca JP; Williams TM; Anthony NJ Bioorg Med Chem Lett; 2010 Aug; 20(15):4328-32. PubMed ID: 20609585 [TBL] [Abstract][Full Text] [Related]
9. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201 [TBL] [Abstract][Full Text] [Related]
10. Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase. Kar P; Knecht V J Phys Chem B; 2012 Jun; 116(22):6269-78. PubMed ID: 22574920 [TBL] [Abstract][Full Text] [Related]
11. Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Muraglia E; Kinzel OD; Laufer R; Miller MD; Moyer G; Munshi V; Orvieto F; Palumbi MC; Pescatore G; Rowley M; Williams PD; Summa V Bioorg Med Chem Lett; 2006 May; 16(10):2748-52. PubMed ID: 16503141 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. Fader LD; Bethell R; Bonneau P; Bös M; Bousquet Y; Cordingley MG; Coulombe R; Deroy P; Faucher AM; Gagnon A; Goudreau N; Grand-Maître C; Guse I; Hucke O; Kawai SH; Lacoste JE; Landry S; Lemke CT; Malenfant E; Mason S; Morin S; O'Meara J; Simoneau B; Titolo S; Yoakim C Bioorg Med Chem Lett; 2011 Jan; 21(1):398-404. PubMed ID: 21087861 [TBL] [Abstract][Full Text] [Related]
13. Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses. Su DS; Lim JJ; Tinney E; Wan BL; Young MB; Anderson KD; Rudd D; Munshi V; Bahnck C; Felock PJ; Lu M; Lai MT; Touch S; Moyer G; DiStefano DJ; Flynn JA; Liang Y; Sanchez R; Perlow-Poehnelt R; Miller M; Vacca JP; Williams TM; Anthony NJ J Med Chem; 2009 Nov; 52(22):7163-9. PubMed ID: 19883100 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435 [TBL] [Abstract][Full Text] [Related]
15. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Domaoal RA; Demeter LM Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341 [TBL] [Abstract][Full Text] [Related]
16. Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Chong P; Sebahar P; Youngman M; Garrido D; Zhang H; Stewart EL; Nolte RT; Wang L; Ferris RG; Edelstein M; Weaver K; Mathis A; Peat A J Med Chem; 2012 Dec; 55(23):10601-9. PubMed ID: 23137340 [TBL] [Abstract][Full Text] [Related]
17. Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses. Tang G; Kertesz DJ; Yang M; Lin X; Wang Z; Li W; Qiu Z; Chen J; Mei J; Chen L; Mirzadegan T; Harris SF; Villaseñor AG; Fretland J; Fitch WL; Hang JQ; Heilek G; Klumpp K Bioorg Med Chem Lett; 2010 Oct; 20(20):6020-3. PubMed ID: 20829038 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors. Xiaohe Z; Yu Q; Hong Y; Xiuqing S; Rugang Z Chem Biol Drug Des; 2010 Oct; 76(4):330-9. PubMed ID: 20731670 [TBL] [Abstract][Full Text] [Related]
19. N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Mitchell ML; Son JC; Lee IY; Lee CK; Kim HS; Guo H; Wang J; Hayes J; Wang M; Paul A; Lansdon EB; Chen JM; Eisenberg G; Geleziunas R; Xu L; Kim CU Bioorg Med Chem Lett; 2010 Mar; 20(5):1585-8. PubMed ID: 20137928 [TBL] [Abstract][Full Text] [Related]
20. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection. Ripamonti D; Maggiolo F Curr Opin Investig Drugs; 2008 Aug; 9(8):899-912. PubMed ID: 18666038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]